NCT01662882

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

An Open Label, Parallel Group, Multicenter Study, Evaluating the Safety and Imaging Characteristics of Florbetapir (18F) in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Avid Radiopharmaceuticals · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Accepted

Summary

Evaluate florbetapir (18F) positron emission tomography (PET) imaging for distinguishing Japanese healthy control subjects, from Japanese subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).

Conditions

• Alzheimer's Disease
• Mild Cognitive Impairment

Interventions

Type	Name	Description
DRUG	florbetapir (18F)	IV injection, 370 MBq(10mCi), single dose

Timeline

• Start date: 2012-10-01
• Primary completion: 2013-02-01
• Completion: 2013-02-01
• First posted: 2012-08-13
• Last updated: 2013-09-19
• Results posted: 2013-09-19

Locations

2 sites across 1 country: Japan